Epicardial Fat Clinical Trial
Official title:
Effects of Semaglutide vs Dulaglutide on Epicardial Adipose Tissue Thickness in Subjects With Type 2 Diabetes and Obesity
Epicardial Fat (EAT), the visceral fat depot of the heart, is a modifiable cardio-metabolic risk factor and therapeutic target. EAT expresses GLP-1 receptors (GLP-1R). GLP-1 receptor agonist liraglutide is known to significantly decrease EAT thickness. However, the effects of GLP-1 receptor agonists semaglutide and dulaglutide on EAT thickness are unknown
This is a retrospective, observational, case control study. Data were obtained from retrospective review of the electronic medical records. Patients were treated with either semaglutide, dulaglutide or metformin as standard of care, during routine clinical practice, regardless of the study. Each patient underwent routine labs and an onsite ultrasound measurement of EAT thickness at baseline and at the routine 12-week follow up visit, as standard of care. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03111693 -
CT Evaluation of Cardiovascular Risk Markers in Obese Patients
|
N/A | |
| Not yet recruiting |
NCT01344694 -
Epicardial Fat, Visceral Fat and Coronary Atherosclerosis
|
N/A |